Browsing Tag
PADCEV
11 posts
PADCEV plus Keytruda shows survival benefit in muscle-invasive bladder cancer regardless of cisplatin eligibility
PADCEV plus Keytruda shows significant survival benefit in cisplatin-eligible muscle-invasive bladder cancer. Find out what the EV-304 data means for treatment standards.
December 19, 2025
Can immunotherapy finally replace chemo in bladder cancer? Keytruda–Padcev combo shows the way
Explore how Merck’s Keytruda and Padcev combo is redefining bladder cancer treatment without chemo. Survival gains, sector impact, and what’s next in focus.
November 24, 2025
Bladder cancer breakthrough: FDA gives Priority Review to Merck’s KEYTRUDA and KEYTRUDA QLEX + PADCEV combinations
Find out how Merck’s KEYTRUDA and new KEYTRUDA QLEX + PADCEV combinations are set to transform treatment for muscle-invasive bladder cancer — read more now
October 23, 2025
Padcev and Keytruda combo cuts bladder cancer recurrence risk by 60% in pivotal Phase 3 win
Discover how the Padcev and Keytruda combination achieved unprecedented survival gains in bladder cancer — read our expert take.
October 19, 2025
Pfizer beats Q2 2025 earnings expectations and raises profit forecast, but long-term growth questions persist
Pfizer beats Q2 2025 estimates and raises profit guidance, but patent expirations and pricing pressures keep long-term growth questions on the table.
August 11, 2025
EC approves PADCEV and KEYTRUDA combo for advanced urothelial cancer treatment
Astellas Pharma Inc. has announced a significant milestone in cancer treatment with the European Commission (EC’s) approval of…
August 28, 2024
Breakthrough in cancer treatment: China approves PADCEV for advanced urothelial cancer
China’s National Medical Products Administration (NMPA) has granted approval for PADCEV (enfortumab vedotin) to treat locally advanced or…
August 20, 2024
Japan’s MHLW grants priority review for PADCEV and KEYTRUDA combo in urothelial cancer
In a significant development in the fight against urothelial cancer, Astellas Pharma Inc. announced that Japan’s Ministry of…
February 18, 2024
Advancing bladder cancer treatment: EMA scrutinizes Astellas-Pfizer’s innovative therapy
A groundbreaking development in bladder cancer treatment is on the horizon as Astellas Pharma Inc. and Pfizer Inc.…
January 28, 2024
Phase 3 EV-302 clinical trial : Seagen, Astellas reveal promising for PADCEV and KEYTRUDA combo
Seagen Inc. and Astellas Pharma Inc. have announced encouraging results from the Phase 3 EV-302 clinical trial, presenting…
October 22, 2023